WallStSmart

Alamar Biosciences, Inc. Common Stock (ALMR)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 28894% more annual revenue ($25.27B vs $87.16M). SYK leads profitability with a 13.2% profit margin vs -49.9%. SYK earns a higher WallStSmart Score of 57/100 (C).

ALMR

Avoid

25

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -1.23

SYK

Buy

57

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ALMR.

SYKSignificantly Overvalued (-57.3%)

Margin of Safety

-57.3%

Fair Value

$224.01

Current Price

$352.25

$128.24 premium

UndervaluedFair: $224.01Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALMR2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
98.9%10/10

Revenue surging 98.9% year-over-year

Debt/EquityHealth
-1.9110/10

Conservative balance sheet, low leverage

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$118.55B9/10

Large-cap with strong market position

Areas to Watch

ALMR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.80B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-33.6%2/10

ROE of -33.6% — below average capital efficiency

Free Cash FlowQuality
$-20.95M2/10

Negative free cash flow — burning cash

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
36.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ALMR

The strongest argument for ALMR centers on Revenue Growth, Debt/Equity. Revenue growth of 98.9% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap.

Bear Case : ALMR

The primary concerns for ALMR are EPS Growth, Market Cap, Return on Equity.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

ALMR profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

ALMR is growing revenue faster at 98.9% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (57/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alamar Biosciences, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Alamar Biosciences, Inc. is a leading biotechnology company focused on developing innovative diagnostic solutions for infectious diseases utilizing its proprietary technology platform. The company is recognized for its ability to provide rapid and precise testing, which enhances clinical decision-making and improves patient outcomes. With a strong commitment to ongoing research and development, Alamar is well-positioned to address pressing medical needs, making it an appealing investment opportunity for institutional investors looking to capitalize on growth within the expanding diagnostics market.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?